论文部分内容阅读
目的 比较恶性肿瘤患者、非恶性肿瘤患者以及恶性肿瘤患者治疗前后胸腹水中 TSGF含量的关系 ,探讨胸腹水中 TSGF含量对恶性肿瘤的早期诊断及治疗意义。方法 对 4 6例非急性炎症和非结核类患者 (对照组 )、5 8例急性炎症和结核患者、1 0 7例恶性肿瘤患者 (治疗前 )及治疗后 4 5例恶性肿瘤患者的胸腹水分别进行 TSGF含量测定 ,比较各组的差异。结果 对照组的阳性率是 4 .3% ,急性炎症和结核患者组的阳性率是 81 .0 % ,与对照组有显著差异 (t=1 0 .7,P<0 .0 1 ) ;恶性肿瘤患者组的阳性率为 86 .9% ,与对照组有显著差异 (t=1 2 .4 ,P<0 .0 1 ) ,但与急性炎症和结核患者组无显著差异 (t=0 .0 1 ,P>0 .0 5 ) ;恶性肿瘤患者组治疗前与治疗后有显著差异(t=4 .5 ,P<0 .0 1 )结论 测定胸腹水中 TSGF含量对恶性肿瘤的早期诊断、疗效观察有着重要的意义
Objective To compare the relationship between TSGF content in pleural effusion and ascites before and after treatment of malignant tumor patients, non-malignant tumor patients and malignant tumor patients, and to explore the early diagnosis and therapeutic significance of pleural fluid and ascites TSGF content in malignant tumors. Methods Forty-six cases of non-acute inflammatory and non-tuberculosis patients (control group), 58 acute and tuberculosis patients, 107 malignant tumor patients (before treatment) and 45 cases of malignant tumor after treatment The levels of TSGF were measured separately and the differences among groups were compared. Results The positive rate was 4.3% in the control group and 81.0% in the acute inflammation and tuberculosis group, which was significantly different from the control group (t = 100.7, P <0.01). Malignant The positive rate of cancer patients was 86.9%, which was significantly different from that of the control group (t = 12.4, P <0.01), but not significantly different from those of patients with acute inflammation and tuberculosis (t = 0. 0 1, P> 0.05). There was a significant difference between before and after treatment in patients with malignant tumor (t = 4.5, P <0.01) Conclusion The early diagnosis of malignant tumors , The efficacy of observation of great significance